Isocitrate dehydrogenase (IDH)1 and IDH2 inhibitors, ivosidenib and enasidenib, which promote myeloid precursor differentiation, are approved for the treatment of adult relapsed or refractory AML in patients with mutant IDH1 and mutant IDH2, respectively (10). The gene discussed is IDH2; the disease is acute myeloid leukemia.